Skip Navigation


European Journal of Heart Failure Advance Access originally published online on May 6, 2009
European Journal of Heart Failure 2009 11(7):691-698; doi:10.1093/eurjhf/hfp062
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/7/691    most recent
hfp062v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yao, K.
Right arrow Articles by Ge, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yao, K.
Right arrow Articles by Ge, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Repeated autologous bone marrow mononuclear cell therapy in patients with large myocardial infarction

Kang Yao1,{dagger}, Rongchong Huang1,2,{dagger}, Aijun Sun1,3,{dagger}, Juying Qian1, Xuebo Liu1, Lei Ge1, Yiqi Zhang1, Shuning Zhang1, Yuhong Niu1, Qibing Wang1, Yunzeng Zou1,3,* and Junbo Ge1,3,*

1 Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, China
2 Department of Cardiology, Dalian Medical University, Dlian, China
3 Institutes of Biomedical Science, Fudan University, 138 Dong'an Road, Shanghai 200032, China

* Corresponding author. Tel: +86 21 64041990 2152, Fax: +86 21 64437078, Email: jbge{at}zs-hospital.sh.cn (J.G.) or zou.yunzeng{at}zs-hospital.sh.cn (Y.Z.)


  Abstract

Aims: We sought to determine whether repeat administration of bone marrow mononuclear cells (BMC) can improve left ventricular function compared with a single infusion in patients with large acute myocardial infarction (AMI).

Methods and results: Thirty-nine patients with a ST-elevation AMI of the anterior wall and a significantly decreased left ventricular ejection fraction (LVEF 20–39%) were randomly assigned to three groups following primary percutaneous coronary intervention: Group A (n = 12) received a single intracoronary infusion of BMC (1.9 ± 1.2 x 108) at 3–7 days after AMI; Group B (n = 15) received BMC administration both at 3–7 days (2.0 ± 1.4 x 108) and at 3 months (2.1 ± 1.7 x 108); and the control group (CON, n = 12) received one placebo injection at 3–7 days. We noted no severe complications associated with the BMC transfer. The increase in LVEF evaluated by magnetic resonance imaging (MRI) after 12 months in Group B (11.7 ± 2.6%) was significantly greater than that in Group A (7.2 ± 1.6%, P < 0.001) or in CON (2.9 ± 2.0%, P < 0.001). Magnetic resonance imaging-derived myocardial infarct size decreased significantly in Group B compared with Group A (11.3 ± 2.7% vs. 6.3 ± 1.6%, P < 0.001).

Conclusion: Data from this preliminary study suggest that repeated BMC administration might be a safe and feasible therapeutic strategy for patients with large AMI.

Key Words: Myocardial infarction • Cell therapy • BMC • Large • Repeated

Received October 14, 2008; Revised January 23, 2009; Accepted March 10, 2009

{dagger} The first three authors contributed equally to the study.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.